. Author manuscript; available in PMC: 2010 Dec 1.

Published in final edited form as: Neurochem Int. 2009 Aug 5;55(8):783–788. doi: 10.1016/j.neuint.2009.07.012

Table 2.

Brain specific protein concentrations in the cerebrospinal fluid from CLN6 affected sheep at different stages of the disease and age-matched controls (ng/l± sem)

	Disease stage
	Aggressive neurodegeneration (5–10 months of age)		Advanced terminal disease (18 – 32 months of age)
Marker	affected (n=6) ^a	control (n=12) ^a	affected (n=5) ^a	control (n=4) ^a

NSE ^b	1.1(0.2)^c	0.6(0.1)	0.8(0.2)	0.2(0.1)
S100 ^b	46.2(13.0)^c	34.3(4.6)	7.1(0.9)	4.0(0.7)
GFAP ^b	0.85(0.3)	0.7(0.1)	undetectable	undetectable

n= the number of animals sampled.

Immunoreactivity equivalent to human protein in μg/l (± sem).

One affected animal sample had NSE and S-100b concentrations of 7.16ng/l and 236ng/l respectively and was excluded as an anomaly. Including it in the data did not result in a significant difference between the affected and control means.